Change Order No. 1 to Project Agreement between Novotech (Australia) Pty Limited and Lexaria (AU) Pty Ltd
This agreement is a change order to a previous project agreement between Novotech (Australia) Pty Limited and Lexaria (AU) Pty Ltd. It updates the budget and key assumptions for clinical trial support services provided by Novotech, reflecting changes in study parameters and responsibilities. The revised terms, effective May 14, 2025, include an updated scope of services, increased subject numbers, and a new budget. All other terms of the original agreement remain unchanged.
EXHIBIT 10.2
Change Order No. 1
Date: as per the last signature date of the Parties
|
Parties
1. | Novotech (Australia) Pty Limited ACN 071 874 881 of Level 19, 66 Goulburn Street, Sydney NSW 2000, Australia (Novotech) |
|
|
2. | Lexaria (AU) Pty Ltd of C/- Suite 1, Level 3, 62 Lygon Street, Carlton, Victoria, 3053, Australia (Sponsor) |
|
|
|
|
Background
A | On December 2, 2024, Novotech and Sponsor entered into a Project Agreement (Project Agreement) pursuant to which Novotech is providing services to support clinical trials to Sponsor. |
|
|
B | The parties agree that this Change Order sets out the amendments to the Project Agreement which are agreed between the Sponsor and Novotech. |
|
|
C | Capitalised terms in this Change Order have the same meaning as in the Project Agreement. |
|
|
D | The parties agree to change the terms of the Project Agreement from May 14, 2025 (Effective Date), as follows: |
|
|
1 | Change Order Details |
|
|
1.1 | This Change Order sets out the changes to the Budget for the Services in the Project Agreement as agreed by the parties. The changes are as a result of changes to the Key Assumptions (Study Assumptions and Responsibilities) as set out in Schedules 1 and 2 hereof. |
|
|
1.2 | The revised Key Assumptions for the Study (Revised Key Assumptions) are set out in Schedules 1 and 2. The parties agree that the Revised Key Assumptions accurately reflect the Study parameters and the Services to be performed by Novotech from the Effective Date. |
|
|
1.3 | The parties agree that all other terms of the Project Agreement remain the same. |
Change Order #01 | Version 6, November 2021 |
Lexaria Bioscience_GLP-1-H24-4_2024-5470 | Page 1 of 14 |
Executed as an Agreement
Signed for and on behalf of Novotech (Australia) Pty Limited by its authorised representative:
|
| Signed for and on behalf of Lexaria (AU) Pty Ltd by its authorised representative:
|
Signature of Chief Commercial Officer
“Barry Murphy”
|
| Signature of Director
“John Docherty”
Signature of Director
“Janice Henrichs”
|
Change Order #01 | Version 6, November 2021 |
Lexaria Bioscience_GLP-1-H24-4_2024-5470 | Page 2 of 14 |
Schedule 1 Scope of Services -
Region- Site- Subject Strategy
REGION | #Previous Subjects | # Revised Subjects |
Australia | 80 | 120 |
TOTAL | 80 | 120 |
Monitoring Visits
REGION | Previous IMVs | Revised IMVs | Previous Remote IMVs | Revised Remote IMVs |
Australia | 21 | 63 | 35 | 21 |
TOTAL | 21 | 63 | 35 | 21 |
Change Order #01 | Version 1, November 2021 |
Lexaria Bioscience_GLP-1-H24-4_2024-5470 | Page 3 of 14 |
Schedule 2 Services Budget
Revised Budget
Direct Fees (AUD) | Revised Total Budget | PA Budget | Change Order Budget |
Medical Writing Start-up | [**] | [**] | [**] |
Drug Development Consulting | [**] | [**] | [**] |
Regulatory and Ethics | [**] | [**] | [**] |
Start-up Activities | [**] | [**] | [**] |
Clinical Site Management | [**] | [**] | [**] |
Study Management | [**] | [**] | [**] |
Data management | [**] | [**] | [**] |
Biostatistics | [**] | [**] | [**] |
Pharmacovigilance | [**] | [**] | [**] |
Medical Monitoring | [**] | [**] | [**] |
Clinical Study Report | [**] | [**] | [**] |
Total Professional Fees | [**] | [**] | [**] |
Discount (20%) | [**] | [**] | [**] |
Total Professional Fees (with discount) | 2,648,963.39 | 2,349,040.44 | 299,922.96 |
Biometrics and/or Pharmacovigilance will be delivered by our Australian team, and applicable for R&D tax rebate. | |||
Hosting Fees (AUD) | |||
Clinical Systems Hosting Fees | [**] | [**] | [**] |
EDC Cost | [**] | [**] | [**] |
Total Hosting Fees | [**] | [**] | [**] |
Total Service Fees (*) | 3,064,066.45 | 2,764,143.49 | 299,922.96 |
* Total Service Fees do not include inflation. Inflation will be applied annually based on CPI. | |||
Pass-through Costs (AUD) | |||
Pass-through Costs | [**] | [**] | [**] |
Investigator Fees | [**] | [**] | [**]1 |
Total Pass-through Costs | 3,918,183.00 | 2,318,390.00 | 1,599,793.00 |
Grand Total | 6,982,249.45 | 5,082,533.49 | 1,899,715.96 |
1 The line item costs with associated specific activities have been redacted to allow the CRO and any third party service provider to maintain competitive negotiations with other sponsors.
Change order # 01 Schedule – | Version 1, November 2021 |
Lexaria Bioscience_Diabetes_2024-5470 | Page 4 of 14 |
Detailed Budget for Services
Budget |
|
|
| TOTAL/REVISED Budget | PA Budget | Change Order Budget | ||||||
Task Description | Pricing Unit | Unit Price (AUD) | Disc Unit Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # CO Units | Total Price (AUD) | Disc Total Price (AUD) |
Medical Writing Start-up |
| 0 | 0 | 0 | ||||||||
Protocol Synopsis - Review and Update | Per Protocol Synopsis | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Protocol writing, QC and finalisation (excluding protocol synopsis) | Per Protocol | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Protocol amendment writing, QC and finalisation- minor amendment (Amendment 1) | Per Minor Amendment | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Protocol amendment writing, QC and finalisation- major amendment (Amendment 3) | Per Major Amendment | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Subtotal |
| [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Drug Development Consulting | - | - | - | - | - | - | - | - | - | - | - | |
Investigator Brochure writing, QC and finalisation (Semaglutide) | Per IB | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
CBD IB update | Per IB | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Tirzepatide IB | Per IB | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Subtotal |
| [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Regulatory and Ethics |
| - | - | - | - | - | - | - | - | - | - | - |
IRB/EC Submission | Per Total Site | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
IRB/EC Submission (Post Initial Submission upto Protocol amendment -v4/v5) | Per Total Site (Major submission) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Change order # 01 Schedule – | Version 1, November 2021 |
Lexaria Bioscience_GLP-1-H24-4_2024-5470 | Page 5 of 14 |
Budget |
|
|
|
| TOTAL/REVISED Budget | PA Budget | Change Order Budget | |||||
Task Description | Pricing Unit | Unit Price (AUD) | Disc Unit Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # CO Units | Total Price (AUD) | Disc Total Price (AUD) |
IRB/EC Submission (Post Initial Submission minor submission PCLs PICF Memos upto PICF v6) | Per Total Site (Minor submission) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Regulatory Submissions | Per country (Reg Submission) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Regulatory Submissions (Post Initial - 1. Arm 5 and for future Site location/PI changes | Per site HA Submission (Updates Post Initial submission) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Regulatory Study Management and Oversight (Start-up) | Per Month (Start-Up) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Regulatory Study Management and Oversight (Recruitment, Treatment & Follow-up) | Per Month (Ex Startup & Closeout) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Informed Consent Preparation, Review and Finalisation | Per Site | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
PICF updates (Post start-up) CO#01 | PICF update per site | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Act as Local Sponsor | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Subtotal |
| [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Start-up Activities |
| - | - | - | - | - | - | - | - | - | - | - |
Kick-off meeting | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Team Training | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
CRA Training Meeting | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Site Feasibility | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Clinical System Set Up | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Project and Operational Plans | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Change order # 01 Schedule – | Version 1, November 2021 |
Lexaria Bioscience_GLP-1-H24-4_2024-5470 | Page 6 of 14 |
Budget |
|
|
|
| TOTAL/REVISED Budget | PA Budget | Change Order Budget | |||||
Task Description | Pricing Unit | Unit Price (AUD) | Disc Unit Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # CO Units | Total Price (AUD) | Disc Total Price (AUD) |
Site Qualification Visits (On-site) | Per QV | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Phone SQVs | Per Phone QV | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Investigator Meeting | Per IM | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Site Contract and Budget Management | Per Site | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Site Contract and Budget Management Post Start-up (CO#01) | Per Site per update | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Site Management- Start up | Per Site Per Month (Start Up) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Vendor Identification and Contracting | Per Vendor | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Subtotal |
| [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Clinical Site Management |
| - | - | - | - | - | - | - | - | - | - | - |
Site Initiation Visits | Per SIV | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Interim Monitoring Visits (Recruitment and Treatment) | Per revised IMV (Rec-Treat) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Co-monitoring visits | Per Co-visits (Rec-Treat) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Offsite -ediary data listing review – fortnight | Per data listing review | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Remote Monitoring Visits | Per revised Remote IMV | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Site Management (Recruitment, Treatment) | Per Site Per Month (Recruitment & Treatment) - SM | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Change order # 01 Schedule – | Version 1, November 2021 |
Lexaria Bioscience_GLP-1-H24-4_2024-5470 | Page 7 of 14 |
Budget |
|
|
|
| TOTAL/REVISED Budget | PA Budget | Change Order Budget | |||||
Task Description | Pricing Unit | Unit Price (AUD) | Disc Unit Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # CO Units | Total Price (AUD) | Disc Total Price (AUD) |
Site Management - Close-Out | Per Site Per Month (Close-Out) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Close-out Visits | Per COV | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Subtotal |
| [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Study Management |
| - | - | - | - | - | - | - | - | - | - | - |
Project Management - Pre-Start-up | Per Month (Pre-Start-Up) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Project Management- Start Up | Per Month (Start-Up) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Project Management- Recruitment and Treatment | Per Month (Recruitment & Treatment) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Project Management- Close-out | Per Month (Close-Out) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Vendor management/communication | Per Month | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Subtotal | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Data management |
| - | - | - | - | - | - | - | - | - | - | - |
Database Design and Set-up | Per Set-Up Stage | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Design and Program Edit Check Specifications | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
External Data Set Up and Programming | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Develop Data Management Plans | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
RTSM- Set Up | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
E-Diary additional updates and programming activities for adding treatment arm 5 | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Change order # 01 Schedule – | Version 1, November 2021 |
Lexaria Bioscience_GLP-1-H24-4_2024-5470 | Page 8 of 14 |
Budget |
|
|
|
| TOTAL/REVISED Budget | PA Budget | Change Order Budget | |||||
Task Description | Pricing Unit | Unit Price (AUD) | Disc Unit Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # CO Units | Total Price (AUD) | Disc Total Price (AUD) |
RTSM additional updates and programming for adding treatment arm 5 | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
EDC programming and updates and programming for adding treatment arm 5 | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Tirzepatide sentinel and replacements arms 1-4 manual programming | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
eDiary programming widening of open hrs window | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Data Management- Recruitment- FU | Per Month (Recruitment, Treatment, Follow-Up) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Medical Coding | Per Month (Recruitment, Treatment, Follow-Up) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
External Data Handling and Transfer | Per Month (Recruitment, Treatment, Follow-Up) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
RTSM- Recruitment- Treatment | Per Month | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
RTSM- Close-out | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Database Lock | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Data Management- Close out | Per Month (Close-Out) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Subtotal |
| [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Biostatistics |
| - | - | - | - | - | - | - | - | - | - | - |
Production of SAP & TFL Shells | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Change order # 01 Schedule – | Version 1, November 2021 |
Lexaria Bioscience_GLP-1-H24-4_2024-5470 | Page 9 of 14 |
Budget |
|
|
|
| TOTAL/REVISED Budget | PA Budget | Change Order Budget | |||||
Task Description | Pricing Unit | Unit Price (AUD) | Disc Unit Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # CO Units | Total Price (AUD) | Disc Total Price (AUD) |
Programming of TLFs- Final Analysis | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Final Statistical Analysis | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
CDISC Conversion (Final) | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Biostatistics Management: Start-up | Per Month (Start-Up) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Biostatistics Management: Maintenance | Per Month (Recruitment, Treatment, Follow-Up) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Biostatistics Management: Close-out | Per Month (Close-Out) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Programming of TLFs for DSUR | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Subtotal |
| [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Pharmacovigilance |
| - | - | - | - | - | - | - | - | - | - | - |
Safety Database Set-up | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Safety Management Plan | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Safety Management and Periodic Reporting | Per Month (Ex. Start-Up) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
SAE Management | Per SAE Report | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
SUSAR Management and Investigator Reporting | Per SUSAR Report | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
DSUR Generation and QC | Per Year | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Subtotal |
| [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Medical Monitoring |
| - | - | - | - | - | - | - | - | - | - | - |
Monthly Oversight - Start up | Per Month (Start-Up) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Monthly Oversight - Recruitment | Per Month (Recruitment) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Change order # 01 Schedule – | Version 1, November 2021 |
Lexaria Bioscience_GLP-1-H24-4_2024-5470 | Page 10 of 14 |
Budget |
|
|
|
| TOTAL/REVISED Budget | PA Budget | Change Order Budget | |||||
Task Description | Pricing Unit | Unit Price (AUD) | Disc Unit Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # Units | Total Price (AUD) | Disc Total Price (AUD) | # CO Units | Total Price (AUD) | Disc Total Price (AUD) |
Monthly Oversight - Treatment | Per Month (Treatment) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Monthly Oversight - Close-out | Per Month (Close-Out) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Subtotal |
| [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Clinical Study Report |
| - | - | - | - | - | - | - | - | - | - | - |
Final Clinical Study Report (CSR) writing, QC and finalisation | Per CSR | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Subtotal |
| [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Medical Writing Start-up |
| [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] |
Drug Development Consulting | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |
Regulatory and Ethics | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |
Start-up Activities | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |
Clinical Site Management | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |
Study Management | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |
Data management | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |
Biostatistics | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |
Pharmacovigilance | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |
Medical Monitoring | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |
Clinical Study Report | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |
Total |
| [**] | [**] | [**] | 2,349,040.44 | [**] | 299,922.96 | |||||
Discount % | [**]% | [**]% | [**]% | |||||||||
Discount $ | [**] | - | [**] | - | [**] | - | ||||||
Grand Total |
| [**] | [**] | 2,349,040.44 | 2,349,040.44 | 299,922.96 | 299,922.96 | |||||
* Total Service Fees do not include inflation. Inflation will be applied annually based on CPI. |
Change order # 01 Schedule – | Version 1, November 2021 |
Lexaria Bioscience_GLP-1-H24-4_2024-5470 | Page 11 of 14 |
Hosting and Lab Estimate |
|
|
|
|
|
|
| |
Task Description | Pricing Unit | Unit Price (AUD) | # Units | Total Price (AUD) | # Units | Total Price (AUD) | # CO Units | Total Price (AUD) |
Hosting Fees |
| - | - | - | - | - | - | - |
Clinical Systems Hosting Fees | Per Month | [**] | [**] | [**] | [**] | [**] | - | - |
Subtotal |
| - | - | [**] | - | [**] | - | - |
Pass-through Cost Estimate |
|
| Revised budget | PA budget | CO#01 budget | |||||
Task Description | Pricing Unit | Unit Price (AUD) | # Units | Total Price (AUD) | # Units | Total Price (AUD) | # CO Units | Total Price (AUD) | ||
Regulatory And IRB/IEC Submission Fees | - | |||||||||
HA/Competent Authority Submission (Initial) | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
IRB/IEC Submission Fee (Initial)- Central | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Post initial HREC submissions (All major submissions to BB HREC upto PA 4/v5 and 4 subsequent) | Per Reg Submission | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Post initial HA submissions | Per Reg Submission | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Subtotal | - | - | [**] | - | [**] | - | [**] | |||
Vendor Costs | - | - | - | - | - | - | - | |||
Drug Storage & Distribution | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Central Lab | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Courier | Per Month | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Marken Fee | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Phone /Administration/ Stationery | Per Month | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Subtotal | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |||
Monitoring Costs | - | - | - | - | - | - | - | |||
Travel – Transport & Accommodation | Per Visit | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Parking for Local Sites | Per Visit | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Subtotal | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |||
Total Pass Through Fees | 1,384,388.00 | 845,955.00 | 538,433.00 | |||||||
All pass through costs are provided as estimates only with the exception of local phone and internal stationery/photocopy fees which will be invoiced at a fixed cost of AUD75 per site per month. | ||||||||||
Details of pass through costs will be provided in Excel and be invoiced on a monthly basis using the exchange rate on the day of invoicing. |
Change order # 01 Schedule – | Version 1, November 2021 |
Lexaria Bioscience_GLP-1-H24-4_2024-5470 | Page 12 of 14 |
Pass-through Cost Estimate |
|
| Revised budget | PA budget | CO#01 budget | |||||
Task Description | Pricing Unit | Unit Price (AUD) | # Units | Total Price (AUD) | # Units | Total Price (AUD) | # CO Units | Total Price (AUD) | ||
Investigator Fees Estimate | - | - | - | - | - | - | - | |||
Investigator Fee - Per Screen Fail Patient | Per Screen Fail Patient | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Investigator Fee - Per Patient | Per Patient | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Site Fees- Set Up | Per Site | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Site Fees- Annual Administration | Per Site Per Year | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Close-out and Archiving Fee | Per Site | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Subtotal | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |||
Total Investigator Fees | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |||
EDC Hosting Estimate | ||||||||||
EDC Professional Services Fee -Study Conduct | Per Month (EDC) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
EDC Hosting/Licensing Fees - Medidata | Per Month (EDC) | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
EDC Professional Services Fee (URL and Coder fee) - Medidata | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Device Service & Subscription fee | Per Study | [**] | [**] | [**] | [**] | [**] | [**] | [**] | ||
Subtotal | [**] | [**] | [**] | [**] | [**] | [**] | [**] | |||
Total EDC Fees | [**] | [**] | [**] | [**] | [**] | [**] | [**]2 | - |
2 The specified activities and associated costs have been redacted to allow the CRO and any third party service provider to maintain competitive negotiations with other sponsors.
Change order # 01 Schedule – | Version 1, November 2021 |
Lexaria Bioscience_GLP-1-H24-4_2024-5470 | Page 13 of 14 |
Schedule 3 Payment Schedule -
The following changes are made to the Security Deposit under the Project Agreement:
Security Payment- Direct Fees ([**]%) | Total (AUD) |
Upon Execution of the Agreement | [**] |
Total | [**] |
Security Payment- Pass-Through Costs ([**]%) | Total (AUD) |
Upon Execution of the Agreement | [**] |
Total | [**]3 |
3 The percentage of the Total Direct Fees and Pass Through Costs, along with the total fee value being provided as a security deposit has been redacted to allow the CRO to maintain competitive negotiations with other sponsors.
Change
Change order # 01 Schedule – | Version 1, November 2021 |
Lexaria Bioscience_GLP-1-H24-4_2024-5470 | Page 14 of 14 |